TY - JOUR
T1 - Clinical application of serologic testing for coronavirus disease 2019 in contemporary cardiovascular practice
AU - Damluji, Abdulla A.
AU - Christenson, Robert H.
AU - Defilippi, Christopher
N1 - Funding Information:
Dr Damluji receives research funding from the Pepper Scholars Program of the Johns Hopkins University Claude D. Pepper Older Americans Independence Center funded by the National Institute on Aging P30-AG021334 and the National Institutes of Health-National Heart, Lung, and Blood Institute K23-HL153771-01. Dr deFilippi receives funding from the National Center for Advancing Translational Science of the National Institutes of Health Award UL1TR003015.
Funding Information:
Dr Christenson discloses honoraria, consulting, and scientific advisory board participation with Siemens Healthineers, Roche Diagnostic (and Medscape), Beckman-Coulter, PixCell, Quidel Corporation, BD Diagnostics and Sphingotec. Dr Christenson receives research funding from Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers, Beckman-Coulter, Mitsubushi, Abbott Diagnostics, Quidel Corporation, Becton Dickinson, Sphingotech (NexusDx), Ortho Clinical Diagnostics and PixCell. Dr deFilippi reports consulting fees from Abbott Diagnostics, FujiRebio, Quidel, Ortho Diagnostics, Roche Diagnostics, and Siemens Healthineers. Dr Damluji has no disclosures to report.
Publisher Copyright:
© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
PY - 2021
Y1 - 2021
N2 - In patients with cardiovascular disease, the use of antibody or serological testing is frequently encountered as the coronavirus disease 2019 pandemic continues to evolve. Antibody testing detects one form of the acquired immunological response to a pathogenic antigen. Once the immune system recognizes a viral antigen or a protein as foreign, a humoral immune response is initiated, which is generally detected by laboratory testing in 5 to 10 days after the initial exposure. While this information is critical from a public health perspective to implement surveillance systems and measures to limit infectivity and transmission rate, the misinterpretation of serologic testing in clinical practice has generated much confusion in the medical community because some attempted to apply these strategies to individual patient’s treatment schemes. In this mini-review, we examine the different serologic-based testing strategies, how to interpret their results, and their public health impact at the population level, which are critical to contain the transmission of the virus in the community within a busy cardiovascular practice. Further, this review will also be particularly helpful as vaccination and immune therapy for coronavirus disease 2019 become available to the society as a whole.
AB - In patients with cardiovascular disease, the use of antibody or serological testing is frequently encountered as the coronavirus disease 2019 pandemic continues to evolve. Antibody testing detects one form of the acquired immunological response to a pathogenic antigen. Once the immune system recognizes a viral antigen or a protein as foreign, a humoral immune response is initiated, which is generally detected by laboratory testing in 5 to 10 days after the initial exposure. While this information is critical from a public health perspective to implement surveillance systems and measures to limit infectivity and transmission rate, the misinterpretation of serologic testing in clinical practice has generated much confusion in the medical community because some attempted to apply these strategies to individual patient’s treatment schemes. In this mini-review, we examine the different serologic-based testing strategies, how to interpret their results, and their public health impact at the population level, which are critical to contain the transmission of the virus in the community within a busy cardiovascular practice. Further, this review will also be particularly helpful as vaccination and immune therapy for coronavirus disease 2019 become available to the society as a whole.
KW - COVID-19
KW - Cardiovascular diseases
KW - Immunity
KW - Serologic test
UR - http://www.scopus.com/inward/record.url?scp=85102537162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102537162&partnerID=8YFLogxK
U2 - 10.1161/JAHA.120.019506
DO - 10.1161/JAHA.120.019506
M3 - Short survey
C2 - 33619984
AN - SCOPUS:85102537162
VL - 10
SP - 1
EP - 9
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
SN - 2047-9980
IS - 5
M1 - e019506
ER -